Becerra v. Dr. Pepper Snapple Group, Inc.
Filing
54
ORDER DENYING 30 MOTION TO TRANSFER AND GRANTING 35 MOTION TO DISMISS by Judge Wiliam H. Orrick. The 47 Administrative Motion to file a response is also denied. Plaintiff may file an amended complaint within 20 days of the date of this Order. (jmdS, COURT STAFF) (Filed on 3/30/2018)
1
2
3
4
UNITED STATES DISTRICT COURT
5
NORTHERN DISTRICT OF CALIFORNIA
6
7
SHANA BECERRA,
Plaintiff,
8
v.
9
10
DR PEPPER/SEVEN UP, INC.,
Defendant.
United States District Court
Northern District of California
11
ORDER DENYING MOTION TO
TRANSFER AND GRANTING MOTION
TO DISMISS
Re: Dkt. No. 30, 35
INTRODUCTION
12
13
Case No. 17-cv-05921-WHO
Plaintiff Shana Becerra alleges that she is a consumer of the soft drink product Diet Dr
14
Pepper. She believed that Diet Dr Pepper would assist in weight loss or healthy weight
15
management due to the use of the term “diet” in the name of the product and on its label, but has
16
since learned that studies and articles suggest that artificial sweeteners, including those used in
17
Diet Dr Pepper, may instead cause weight gain. She brings this putative class action on behalf of
18
herself and a California class of similarly-situated consumers for damages and equitable relief,
19
including an injunction to stop defendant Dr Pepper/Seven Up, Inc. (“Dr Pepper”) from marketing
20
its Diet Dr Pepper product as “diet.” While Dr Pepper moves to transfer this action to the United
21
States District Court for the Eastern District of Texas pursuant to 28 U.S.C. § 1404(a), the case
22
belongs here--it has a California plaintiff who was injured in California and chose this venue. Dr
23
Pepper also moves to dismiss plaintiff’s Second Amended Complaint (“SAC”) in its entirety, and I
24
agree with its contention that it is not plausible that a reasonable consumer would believe that
25
drinking Diet Dr Pepper would assist in weight loss, beyond the fact that it has no calories.
26
Accordingly, I DENY Dr Pepper’s motion to transfer venue but GRANT its motion to dismiss
27
with leave to amend
28
.
BACKGROUND
1
Dr Pepper is a Delaware corporation with its principal place of business in Plano, Texas.
2
3
SAC ¶ 7. It first introduced Diet Dr Pepper, a soft drink product, in 1962. SAC ¶ 11. It “uses the
4
term ‘diet’ to market Diet Dr[] Pepper because the product is sweetened with a non-caloric
5
artificial sweetener, aspartame, rather than sugar.” Id. ¶ 14. Plaintiff alleges that “[a]lthough
6
aspartame does not contain calories, scientific research demonstrates that it, like other nonnutritive
7
sweeteners, is likely to cause weight gain.” Id. ¶ 17. She cites a number of studies and articles
8
discussing aspartame’s effects on the body and their findings in her SAC.
Plaintiff is a resident of Santa Rosa, California who has struggled with obesity since
9
childhood. She has been a regular purchaser of Diet Dr Pepper for over thirteen years. SAC ¶¶
11
United States District Court
Northern District of California
10
46–47. She purchased the product believing that its prominent use of the term “diet” on its label
12
and in its advertising indicated “that it would contribute to healthy weight management, and, due
13
to its lack of calories, would not cause her to gain weight.” Id. ¶ 47. She alleges that she would
14
not have purchased the product at the price she paid, or perhaps at all, had defendant not marketed
15
the product as “diet.” Id. ¶ 48.
16
Plaintiff brings suit on behalf of herself and a California class alleging false and
17
misleading advertising, in violation of California’s False Advertising Law (“FAL”), Consumers
18
Legal Remedies Act (“CLRA”), and Unfair Competition Law (“UCL”), as well as breach of both
19
express and implied warranty.1 Defendant moves to transfer venue to its home state of Texas and
20
to dismiss the action in its entirety.
LEGAL STANDARD
21
I.
22
Motion to Transfer
Granting a transfer of venue pursuant to 28 U.S.C. § 1404(a) requires two findings. First,
23
24
the district court must determine that the transferee court is one “where the action might have been
25
brought.” Hatch v. Reliance Ins. Co., 758 F.2d 409, 414 (9th Cir. 1985) (internal quotation marks
26
1
27
28
On the same day this action was initiated, two New York consumers—also represented by
plaintiff’s counsel—filed a similar suit against Dr Pepper in New York on behalf of that state’s
consumers. See Excevarria v. Dr Pepper Snapple Group, Inc., No. 1:17-cv-7957 (S.D.N.Y. filed
on Oct. 16, 2017).
2
1
omitted). Second, as part of completing an “individualized, case-by-case consideration of
2
convenience and fairness,” Jones v. GNC Franchising, Inc., 211 F.3d 495, 498 (9th Cir. 2000), the
3
district court must find “that the convenience of parties and witnesses in the interest of justice
4
favor[s] transfer.” Hatch, 758 F.2d at 414 (internal quotation marks omitted). Importantly, the
5
Ninth Circuit has held that a “defendant must make a strong showing of inconvenience to warrant
6
upsetting the plaintiff’s choice of forum.” Decker Coal Co. v. Commonwealth Edison Co., 805
7
F.2d 834, 843 (9th Cir. 1986).
As part of its convenience analysis, the court must weigh a variety of “private and public
8
interest factors affecting the convenience of the forum.” Decker Coal, 805 F.2d at 843. Courts in
10
this district consider the following factors: (i) plaintiff’s choice of forum; (ii) convenience of the
11
United States District Court
Northern District of California
9
parties; (iii) convenience of the witnesses; (iv) ease of access to the evidence; (v) familiarity of
12
each forum with the applicable law; (vi) feasibility of consolidation with other claims; (vii) any
13
local interest in the controversy; and (vii) the relative court congestion and time to trial in each
14
forum. See, e.g., Lax v. Toyota Motor Corp., 65 F. Supp. 3d 772, 776 (N.D. Cal. 2014); Barnes &
15
Noble, Inc. v. LSI Corp., 823 F. Supp. 2d 980,993 (N.D. Cal. 2011); Vu v. Ortho-McNeil Pharm.,
16
Inc., 602 F. Supp. 2d 1151, 1156 (N.D. Cal. 2009).
17
18
II.
Motion to Dismiss
Under Federal Rule of Procedure 12(b)(6), a district court must dismiss a complaint if it
19
fails to state a claim upon which relief can be granted. To survive a Rule 12(b)(6) motion to
20
dismiss, the plaintiff must allege “enough facts to state a claim to relief that is plausible on its
21
face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). A claim is facially plausible when
22
the plaintiff pleads facts that “allow[] the court to draw the reasonable inference that the defendant
23
is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citation
24
omitted). There must be “more than a sheer possibility that a defendant has acted unlawfully.” Id.
25
While courts do not require “heightened fact pleading of specifics,” a plaintiff must allege facts
26
sufficient to “raise a right to relief above the speculative level.” Twombly, 550 U.S. at 555, 570.
27
In deciding whether the plaintiff has stated a claim upon which relief can be granted, the
28
court accepts the plaintiff’s allegations as true and draws all reasonable inferences in favor of the
3
1
plaintiff. See Usher v. City of Los Angeles, 828 F.2d 556, 561 (9th Cir. 1987). However, the court
2
is not required to accept as true “allegations that are merely conclusory, unwarranted deductions of
3
fact, or unreasonable inferences.” In re Gilead Scis. Sec. Litig., 536 F.3d 1049, 1055 (9th Cir.
4
2008).
Claims sounding in fraud or mistake are subject to the heightened pleading standard of
5
6
Federal Rule of Civil Procedure 9(b), which requires that such claims “state with particularity the
7
circumstances constituting fraud or mistake,” Fed. R. Civ. P. 9(b), including “the who, what,
8
when, where, and how of the misconduct charged.” Vess v. Ciba-Geigy Corp. USA, 317 F.3d
9
1097, 1106 (9th Cir. 2003) (internal quotation marks and citation omitted). “The plaintiff must set
forth what is false or misleading about a statement, and why it is false.” Id. The allegations of
11
United States District Court
Northern District of California
10
fraud “must be specific enough to give defendants notice of the particular misconduct which is
12
alleged to constitute the fraud charged so that they can defend against the charge and not just deny
13
that they have done anything wrong.” Swartz v. KPMG LLP, 476 F.3d 756, 764 (9th Cir. 2007).
If the court dismisses a complaint, it “should grant leave to amend even if no request to
14
15
amend the pleading was made, unless it determines that the pleading could not possibly be cured
16
by the allegation of other facts.” Lopez v. Smith, 203 F.3d 1122, 1127 (9th Cir. 2000). In making
17
this determination, the court should consider factors such as “the presence or absence of undue
18
delay, bad faith, dilatory motive, repeated failure to cure deficiencies by previous amendments,
19
undue prejudice to the opposing party and futility of the proposed amendment.” See Moore v.
20
Kayport Package Express, 885 F.2d 531, 538 (9th Cir. 1989).
DISCUSSION
21
22
I.
Motion to Transfer
23
Neither party disputes that this case is properly brought here but could also have been
24
brought in the Eastern District of Texas, as defendant is headquartered there. The question is
25
whether the relevant convenience and fairness factors weigh in favor of transfer or retention.
26
While the strong presumption in favor of plaintiff’s choice of forum is somewhat dampened due to
27
the class allegations, see Lou v. Belzberg, 834 F.2d 730, 739 (9th Cir. 1987), I nonetheless find
28
that plaintiff’s choice is entitled to some deference, especially given the significant local interest in
4
1
the controversy. She, as well as each member of the proposed class, is either a resident of this
2
district or a district within California. Moreover, her alleged injuries are the result of purchasing
3
and consuming Diet Dr Pepper within this state’s boundaries, and this action is based on
4
California consumers relying on California-specific marketing and sale efforts.
Defendant’s strongest argument in favor of transfer is that it will serve judicial economy,
5
6
as defendant has also moved to transfer the New York-based Excevarria v. Dr Pepper Snapple
7
Group, Inc., No. 1:17-CV-07957 (S.D.N.Y. 2017) action to the Eastern District of Texas. That
8
has not happened yet. Given that any such transfer is speculative at this stage, and considering the
9
local interest in the controversy and deference to plaintiff’s choice of forum, defendant has failed
to make the strong showing of inconvenience necessary to grant transfer. I DENY defendant’s
11
United States District Court
Northern District of California
10
motion to transfer.
12
13
14
II.
Motion to Dismiss
A. Express Preemption by the NLEA
Dr Pepper moves to dismiss plaintiff’s claims on the grounds that they are expressly
15
preempted by Congress and the FDA’s approval of the use of “diet” as part of a soft drink brand
16
name, like “Diet Dr Pepper,” in the Nutrition Labeling and Education Act of 1990 (“NLEA”).
17
The Supremacy Clause of Article VI of the Constitution empowers Congress to make laws that
18
preempt state laws. U.S. Const. Art. VI, cl. 2; Armstrong v. Exceptional Child Ctr., Inc., 135 S.Ct.
19
1378, 1383 (2015). Congress may exert this power through express preemption or conflict
20
preemption––here, defendant argues only that express preemption applies.
21
“In analyzing express preemption, we ‘start with the assumption that the historic police
22
powers of the States were not to be superseded by the Federal Act unless that was the clear and
23
manifest purpose of Congress.’” Astiana v. Hain Celestial Grp., Inc., 783 F.3d 753, 757 (9th Cir.
24
2015) (quoting Rice v. Santa Fe Elevator Corp., 331 U.S. 218, 230 (1947)). This assumption
25
applies not only “to the question whether Congress intended any pre-emption at all,” but also “to
26
questions concerning the scope of its intended invalidation of state law . . . .” Medtronic, Inc. v.
27
Lohr, 518 U.S. 470, 485 (1996) (emphasis in original). “Where there is an express preemption
28
clause applicable to a provision of the FDCA, the Court must determine whether the state law at
5
1
issue falls within the scope of that preemption.” Sciortino v. Pepsico, Inc., 108 F. Supp. 3d 780,
2
798 (N.D. Cal. 2015) (citing Altria Grp., Inc. v. Good, 555 U.S. 70, 76 (2008)). Courts “have a
3
duty to accept the reading that disfavors pre-emption” when such a reading is plausible. Bates v.
4
Dow Agrosciences LLC, 544 U.S. 431, 449 (2005).
“The purpose of Congress is the ultimate touchstone in every pre-emption case.”
6
Medtronic, 518 U.S. at 485 (internal quotation marks and citations omitted). Congress’s intent
7
“primarily is discerned from the language of the pre-emption statute and the ‘statutory framework’
8
surrounding it.” Id. at 486. “Also relevant, however, is the structure and purpose of the statue as a
9
whole, as revealed not only in the text, but through the reviewing court’s reasoned understanding
10
of the way in which Congress intended the statute and its surrounding regulatory scheme to affect
11
United States District Court
Northern District of California
5
business, consumers, and the law.” Id. (internal citations omitted).
Turning to the relevant statute, the NLEA amended the Food, Drug, & Cosmetic Act
12
13
(“FDCA”) to “establish[] uniform food labeling requirements, including the familiar and
14
ubiquitous Nutrition Facts Panel found on most food packages,” Lilly v. ConAgra Foods, Inc., 743
15
F.3d 662, 664 (9th Cir. 2014), as well as “‘to establish the circumstances under which claims may
16
be made about nutrients in foods.’” Chacanaca v. Quaker Oats Co., 752 F. Supp. 2d 1111, 1116
17
(N.D. Cal. 2010) (quoting H.R. Rep. No. 101-538, at 7 (1990), reprinted in 1990 U.S.C.C.A.N.
18
3336, 3337). The many subsections of 21 U.S.C. § 343 establish the conditions under which food
19
is considered “misbranded,” including “[i]f its labeling is false or misleading . . . .” 21 U.S.C.
20
§343(a). Section 343(r) imposes specific labeling requirements governing “nutrition levels and
21
health-related claims” made on product labels. Section 343(r)(2)(D), however, exempts from
22
certain requirements a claim
which uses the term ‘diet’ and is contained in the label or labeling of a soft drink if (i) such
claim is contained in the brand name of such soft drink, (ii) such brand name was in use on
such soft drink before October 25, 1989, and (iii) the use of the term ‘diet’ was in
conformity with section 105.66 of title 21 of the Code of Federal Regulations.
23
24
25
21 U.S.C. § 343(r)(2)(D). “Such a claim is subject to paragraph (a),” id., which provides that a
26
food shall be deemed misbranded “[i]f its labeling is false or misleading . . . .” 21 U.S.C. §
27
343(a).
28
6
Section 343-1 of the NLEA expressly prohibits a state or local government from
1
2
establishing “any requirement respecting any claim . . . made in the label or labeling of food that is
3
not identical to the requirement of section 343(r) . . . .” 21 U.S.C. § 343-1(a)(5). “The phrase ‘not
4
identical to’ means ‘that the State requirement directly or indirectly imposes obligations or
5
contains provisions concerning the composition or labeling of food [that] . . . [a]re not imposed or
6
contained in the applicable [federal regulation] . . . or [d]iffer from those specifically imposed or
7
contained in the applicable [federal regulation].’” Lilly, 743 F.3d at 665 (quoting 21 C.F.R. §
8
100.1(c)(4))).
Placed in the context of the statutory framework and the plain language of the statute,
9
defendant’s express preemption argument fails. The NLEA does not affirmatively approve of the
11
United States District Court
Northern District of California
10
use of “diet” in soft drink brand names like “Diet Dr Pepper,” but instead exempts it from certain
12
labeling requirements to which other nutrition level and health-related claims are subjected. See
13
21 U.S.C. § 343(r)(2)(D).2 Section 343-1 preempts state laws that are “not identical to the
14
requirement of section 343(r),” but Diet Dr Pepper is not subject to Section 343(r); it is
15
specifically exempt from Section 343-1 and is instead subject to Section 343(a). Section 343-1
16
does not address Section 343(a). Even if it did, the state laws under which plaintiff brings suit––
17
California’s UCL, FAL, CLRA, and Sherman Law––impose identical requirements to Section
18
343(a) in that they also prohibit false and misleading advertising. See, e.g., Larsen v. Trader Joe’s
19
Co., 917 F. Supp. 2d 1019, 1023 (N.D. Cal. 2013) (“[W]hile federal law does prohibit state food
20
labeling requirements that are not identical to federal requirements, the FDCA and California law
21
contain identical prohibitions on false or misleading labeling.”); Becerra v. Coca-Cola Co., No. C
22
2
23
24
25
26
27
28
Nor have the corresponding FDA regulations that defendant cites affirmatively approved the use
of “diet” in soft drinks such as “Diet Dr Pepper.” See Mot. at 12–13. The only regulation that
expressly addresses the use of the term “diet” is 21 C.F.R. § 101.13(q)(2), which provides: “A
soft drink that used the term diet as part of its brand name before October 25, 1989, and whose use
of that term was in compliance with 105.66 of this chapter as that regulation appeared in the Code
of Federal Regulations on that date, may continue to use that term as part of its brand name,
provided that its use of the term is not false or misleading . . . .” As discussed, however,
California law contains an identical prohibition of “false or misleading” advertising. The
remaining FDA regulations on calorie-free products (21 C.F.R. § 101.60(b)), sugar-free products
(21 C.F.R § 101.60(c)), and products containing aspartame (21 C.F.R. § 172.804) do not address
the use of the term “diet” in conjunction with these types of products, which is the particular term
giving rise to plaintiff’s claims.
7
1
17-05916 WHA, 2018 WL 1070823, at *2 (N.D. Cal. Feb. 27, 2018)3; accord Ebner v. Fresh,
2
Inc., 838 F.3d 958, 965 (9th Cir. 2016) (finding no express preemption of California’s Sherman
3
Law by similar section of NLEA prohibiting “false or misleading” branding of cosmetics because
4
federal and state duties were identical). Given that California law is entirely consistent with and
5
indeed identical to the NLEA, there is no preemption of plaintiff’s claims.
B. California’s Safe Harbor Doctrine
6
Dr Pepper also moves to dismiss plaintiff’s FAL, CLRA, and UCL claims on the grounds
7
that they are barred by California’s safe harbor doctrine. “In California, unfair competition claims
9
are subject to the safe harbor doctrine, which precludes plaintiff[] from bringing claims based on
10
‘actions the Legislature permits.’” Ebner v. Fresh, Inc., 838 F.3d 958, 963 (9th Cir. 2016) (citing
11
United States District Court
Northern District of California
8
Cel-Tech Commc’ns, Inc. v. L.A. Cellular Tel. Co., 20 Cal. 4th 163, 184 (1999)). “To fall within
12
the safe harbor, the challenged conduct must be affirmatively permitted by statute––the doctrine
13
does not immunize from liability conduct that is merely not unlawful.” Id. This includes not only
14
California statutes, but also federal statutes and regulations. See Davis v. HSBC Bank Nevada,
15
N.A., 691 F.3d 1152, 1164 (9th Cir. 2012).
16
California’s safe harbor doctrine does not apply because no statute or regulation
17
“affirmatively permit[s]” the use of the term “diet” in soft drink labels, as discussed above. See
18
Becerra v. Coca-Cola Co., 2018 WL 1070823, at *3. Instead, the NLEA makes it “merely not
19
unlawful” to use the term “diet” if certain conditions are met; compliance with a federal statute or
20
regulation does not establish express authorization. California’s safe harbor doctrine does not bar
21
plaintiff’s claims.
22
3
23
24
25
26
27
28
Defendant filed a Notice of Supplemental Authority in support of its Motion to Dismiss. See
Dkt. No. 46. The local rules permit a party to submit such a statement of recent decision, but
explicitly specify that such a statement should “contain[] a citation to and provid[e] a copy of the
new opinion––without argument.” Civil L-R 7-3(d)(2) (emphasis added). I agree with plaintiff
that defendant’s notice clearly violates this rule, as it not only summarizes the favorable portions
of the opinion only but also proceeds to apply the opinion’s reasoning to this case. The solution,
however, is not to grant plaintiff’s motion for leave to file an additional response, see Dkt. No. 47,
and welcome even further argument, including a reply from defendants, see Dkt. No. 48. In the
spirit of the rule, which indicates that there shall be no argument at all, I strike defendant’s
argument as contained in both the notice and reply, and I deny plaintiff’s motion for leave to file a
response. I consider the complete opinion issued in the Becerra v. Coca-Cola Co. case, but not
the parties’ argument, in this decision.
8
1
2
C. Plaintiff’s Unfair Competition Claims
Dr Pepper finally moves to dismiss plaintiff’s claims on the basis that her deception
3
argument is implausible because no reasonable consumer would be misled by the term “diet” in
4
the context of a diet soft drink, nor do the studies and articles referenced in the Complaint
5
establish that Diet Dr Pepper actually causes weight gain. In opposition, plaintiff argues that she
6
plausibly alleges that consumers understand “diet” to mean “useful in regulating healthy body
7
weight,” Opp. at 19, and that it is not her burden at the pleadings stage to prove causation.
Plaintiff’s FAL, CLRA, and UCL claims are governed by the “reasonable consumer” test,
9
which requires that plaintiff “show that members of the public are likely to be deceived.” Ebner,
10
838 F.3d at 965 (9th Cir. 2016) (internal quotation marks and citations omitted). “This requires
11
United States District Court
Northern District of California
8
more than a mere possibility that [the] label ‘might conceivably be misunderstood by some few
12
consumers viewing it in an unreasonable manner.’” Id. (quoting Lavie v. Procter & Gamble Co.,
13
105 Cal. App. 4th 496, 508 (2003)). “Rather, the reasonable consumer standard requires a
14
probability ‘that a significant portion of the general consuming public or of targeted consumers,
15
acting reasonably in the circumstances, could be misled.’” Id.
16
While the Ninth Circuit has explained that “California courts[] have recognized that
17
whether a business practice is deceptive will usually be a question of fact not appropriate for
18
decision on demurrer,” “[d]ecisions granting motions to dismiss claims under the Unfair
19
Competition Law have occasionally been upheld.” Williams v. Gerber Prods. Co., 552 F.3d 934,
20
938–39 (9th Cir. 2008). In Ebner, for example, a plaintiff brought suit under the unfair
21
competition laws against a cosmetics company alleging that its lip product was deceptive because
22
the net weight accurately indicated the included product, but the tube design’s screw mechanism
23
only allowed 75% of the product to advance up the tube, leaving the remaining 25% inaccessible.
24
838 F.3d at 961–62. The Ninth Circuit affirmed the district court’s dismissal because it was
25
implausible that a rational consumer would make the assumption that there was no further product
26
in the tube once using up the initial 75% when the remainder was plainly visible. Id. at 966. “And
27
even if some consumers might hazard such an assumption, the [product] [wa]s not false and
28
deceptive merely because the remaining product quantity m[ight have been] unreasonably
9
1
misunderstood by an insignificant and unrepresentative segment of the class of persons that may
2
purchase the product.” Id. (internal quotation marks, alterations, and citation omitted).
3
In a recent memorandum disposition, the Ninth Circuit also affirmed the district court’s
4
dismissal of a similar suit against Starbucks, the coffee company, alleging that its labeling of the
5
volume of iced beverages was deceiving because they did not actually contain the stated volume
6
of liquid, but rather contained some lesser amount of liquid, plus ice. See Forouzesh v. Starbucks
7
Corp., No. 16-56366, slip op. at 2 (9th Cir. Mar. 12, 2018). The panel reasoned that “[t]he
8
statutory claims fail as a matter of law because no reasonable consumer would think (for example)
9
that a 12-ounce ‘iced’ drink, such as iced coffee or iced tea, contains 12 ounces of coffee or tea
10
United States District Court
Northern District of California
11
and no ice.” Id.
And in a very similar case to this one alleged against the Coca-Cola Company by the same
12
plaintiff here, Judge William Alsup dismissed plaintiff’s case, reasoning that “a reasonable
13
consumer would simply not look at the brand name Diet Coke and assume that consuming it,
14
absent any lifestyle change, would lead to weight loss.” Becerra v. Coca-Cola Co., 2018 WL
15
1070823, at *3. Judge Alsup added that “Becerra further fails to allege facts showing how a
16
reasonable consumer would infer from the example Diet Coke advertisements that consumption
17
would lead to weight loss.” Id. at *4.
18
As in the Coca-Cola action, plaintiff theorizes that the term “diet” leads “consumers [to]
19
reasonably believe that [defendant’s] product will assist in weight loss, or at least healthy weight
20
management, for example, by not causing weight gain.” SAC ¶ 15. Plaintiff’s argument does not
21
pass muster. Nothing on the label, packaging, or advertising of Diet Dr Pepper makes the claim or
22
even suggests that the product will assist in weight loss or healthy weight management. It is not
23
marketed as a health food product, and plaintiff does not allege otherwise.
24
Plaintiff alleges only that defendant “tout[s] Diet Dr Pepper as ‘diet,’ and containing zero
25
calories.” Id. ¶ 39. But Diet Dr Pepper is a “diet” product relative to regular Dr Pepper, because
26
Diet Dr Pepper contains zero calories. A reasonable consumer knows that this is and always has
27
been true of soft drinks generally––“diet” soft drinks are simply lower calorie or calorie-free
28
versions of their sugar-laden counterparts. A reasonable consumer would have no basis to infer
10
1
anything more from Diet Dr Pepper’s label or advertising than that it is a calorie-free soft drink.
2
Nor does plaintiff provide any evidence that a reasonable consumer understands “diet” in the
3
context of soft drinks to mean otherwise. As in the Starbucks and Coca-Cola cases, that a small
4
number of persons might unreasonably misunderstand the label does not render the product’s label
5
deceptive within the meaning of California’s unfair competition laws. Plaintiff’s theory of
6
deception fails to pass the “reasonable consumer” test. Accordingly, her unfair competition claims
7
must be dismissed.
8
In the interest of thoroughness should plaintiff seek to amend, I address Dr Pepper’s
9
second argument regarding the studies and articles cited in the SAC. It asserts that the studies and
articles referenced fail to support plaintiff’s premise that aspartame actually causes weight gain.
11
United States District Court
Northern District of California
10
While plaintiff is correct that she need not scientifically prove causation at the pleading stage, she
12
must nonetheless plausibly allege it. The problem with the studies she cites is not that they
13
provide conflicting conclusions or create some factual dispute, as was the case in Krommenhock v.
14
Post Foods, LLC, 255 F. Supp. 3d 938 (N.D. Cal. 2017), which plaintiff relies on. Instead, the
15
studies do not allege causation at all––at best, they support merely a correlation or relationship
16
between artificial sweeteners and weight gain, or risk of weight gain. See, e.g., SAC ¶ ¶ 19
17
(“‘[D]ata ... support the existence of an association between artificially-sweetened beverage
18
consumption and weight gain . . . .’”) (emphasis added); ¶ 21 (“‘[F]requent consumers of these
19
sugar substitutes may also be at increased risk of excessive weight gain . . . .’”) (emphasis added);
20
¶ 27 (“[A]rtificial sweeteners did not lead to any significant weight loss . . . .”). But correlation is
21
not causation, neither for purposes of science nor the law.
22
If plaintiff provided credible studies that support that Diet Dr Pepper or aspartame causes
23
weight gain, that showing would be sufficient to establish the plausibility of plaintiff’s theory even
24
if Dr Pepper replied with many more that disclaimed it. But plaintiff’s SAC fails to cite even a
25
single study that concludes that there is a causative link between aspartame and weight gain. This
26
is a separate and independent reason to grant defendant’s motion to dismiss.
27
28
D. Breach of Warranty Claims
Finally, Dr Pepper moves to dismiss plaintiff’s claims for breach of express and implied
11
1
warranty on the grounds that plaintiff fails to allege that Diet Dr Pepper is unfit for consumption
2
or otherwise breaches a promise made by the label. As I have already concluded that plaintiff’s
3
theory that the term “diet” indicates usefulness with weight loss is implausible, plaintiff’s express
4
warranty claim, which rests on the same theory, must also fail. The term “diet” as it appears on
5
Diet Dr Pepper’s label does not create an express warranty to consumers that the product will
6
assist with weight loss. Because plaintiff acknowledges in opposition that “her implied warranty
7
claims are coextensive with her express warranty claims,” Opp. at 21, her implied warranty claim
8
also fails. Plaintiff’s express and implied warranty claims are DISMISSED.
CONCLUSION
9
10
For the foregoing reasons, the Motion to Transfer is DENIED and the Motion to Dismiss
United States District Court
Northern District of California
11
the Second Amended Complaint is GRANTED with leave to amend. Plaintiff may file an
12
amended complaint within 20 days of the date of this Order.
13
14
IT IS SO ORDERED.
Dated: March 30, 2018
15
16
William H. Orrick
United States District Judge
17
18
19
20
21
22
23
24
25
26
27
28
12
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?